Compare ProShares Ultra Bitcoin ETF (BITU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bitcoin ETF vs Merck & Co., Inc. — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.68, while Merck & Co., Inc. trades at $121.82 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while ProShares Ultra Bitcoin ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITU | MRK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.41 | $129.52 |
52-Week Low | $8.12 | $77.60 |
Market Cap | — | $298.31B |
Enterprise Value | — | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $124.03, up 0.4% on the day, with a bullish technical signal and strong analyst support. The company reported solid earnings beats in recent quarters, including Q1 2026's better-than-expected loss, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth efforts amid competitive pressures.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include patent expirations and rising debt. With a consensus price target of $137.30 offering ~11% upside, the stock presents a compelling opportunity for growth-oriented investors, though macroeconomic and regulatory headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
